Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-13

Study Completion Date

2019-01-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ENCORE Study is designed to evaluate the repeat administration of the S8 Sinus Implant in chronic sinusitis (CS) patients with recurrent nasal polyps.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Performance of the Steroid-Releasing S8 Sinus Implant

NCT01894503

Chronic Sinusitis

COMPLETED PHASE2

A Clinical Evaluation of PROPEL® Contour Sinus Implant

NCT04858802

Chronic Rhinosinusitis (Diagnosis)

COMPLETED NA

Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis

NCT00912405

Chronic Sinusitis

COMPLETED NA

In-office Placement of the Propel Mini Sinus Implant in the Frontal Sinus Ostia

NCT02880514

Chronic Sinusitis

COMPLETED NA

Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps

NCT01732536

Chronic Sinusitis Nasal Polyps

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ENCORE Study is a prospective open-label, non-randomized, multicenter study in CS patients who had undergone prior endoscopic sinus surgery (ESS) including bilateral total ethmoidectomy and present with bilateral ethmoid polyposis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Sinusitis Nasal Polyposis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

S8 Sinus Implant

corticosteroid-eluting sinus implant containing 1350 mcg of mometasone furoate (MF)

Group Type EXPERIMENTAL

S8 Sinus Implant

Intervention Type COMBINATION_PRODUCT

In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

S8 Sinus Implant

In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient has provided written informed consent using a form approved by the reviewing institutional review board (IRB) and sponsor.
2. Patient is ≥ 18 years of age.
3. Patient is willing and able to comply with protocol requirements.
4. Patient has a confirmed diagnosis of CS with nasal polyps, as defined in the 2016 "International Consensus Statement on Allergy and Rhinology".
5. Patient has undergone prior ESS including bilateral total ethmoidectomy at least 90 days prior to screening.
6. Patient has evidence of bilateral ethmoid sinus obstruction due to polyposis warranting intervention (polyp grade ≥ 2 on each side).
7. Patient is able to tolerate daily use of Mometasone Furoate Nasal Spray (MFNS).
8. Patient is able to tolerate topical/local anesthesia.
9. In the opinion of the investigator, patient's ethmoid sinus anatomy is amenable to in-office bilateral placement of the S8 Sinus Implant (i.e., able to pass into the middle meatus on both sides the S8 Sinus Implant with 20 mm in nominal length and 7 mm in compressed diameter).
10. Female patients of reproductive potential must not be pregnant or nursing and must agree to not become pregnant during their participation in the study.
11. Female patients of childbearing potential must agree to use consistent and acceptable method(s) of birth control during their participation in the study.

Exclusion Criteria

1. Patient has extensive ethmoid sinus polyp grade (grade 4 on at least one side).
2. Patient has extensive adhesions/synechiae (grade 3 or 4).
3. Patient has used parenteral and injected steroids (e.g., Kenalog injection) during 30 days prior to the baseline procedure.
4. Patient has used oral steroids, budesonide or other sinus steroid irrigations/rinses, nebulized steroids administered nasally or budesonide drops during 14 days prior to the baseline procedure.
5. Patient has oral-steroid dependent condition such as chronic obstructive pulmonary disease (COPD) or asthma.
6. Patient has known history of allergy or intolerance to corticosteroids or mometasone furoate.
7. Patient has used monoclonal antibodies for asthma, allergies or nasal polyps (e.g., Dupixent, Nucala, Xolair) during 30 days prior to the baseline procedure.
8. Patient requires monoclonal antibodies for asthma, allergies or nasal polyps during the duration of the study.
9. Patient has presence of physical obstruction that would preclude access and placement of the S8 Sinus Implant in the middle meatus (e.g., severe septal deviation, septal spur, very small middle meatus, total obstruction of the sinonasal passage with severe adhesion, scarring, polypoid edema or polyps).
10. Patient has known history of human immunodeficiency virus (HIV) or immunoglobulin G or A subclass deficiency.
11. Patient has clinical evidence of acute sinusitis (AS), as defined in the 2016 "International Consensus Statement on Allergy and Rhinology".
12. Patient has clinical evidence or suspicion of invasive fungal sinusitis (e.g., bone erosion on prior computed tomography (CT) scan, necrotic sinus tissue).
13. Patient has evidence of severe concomitant disease or condition expected to compromise survival or ability to complete assessments during the 365-day study follow-up period (e.g., cancer).
14. Patient is currently participating in another clinical study.
15. Patient has previously undergone ESS and experienced a cerebrospinal fluid (CSF) leak or has residual compromised vision as a result of a complication in a prior ESS procedure.
16. Patient has known dehiscence of the lamina papyracea.
17. Patient has evidence of active tuberculosis or active viral illness (e.g., ocular herpes simplex, chickenpox, measles).
18. Patient has known history or diagnosis of glaucoma or ocular hypertension (prior ocular exam with intraocular pressure of \>21 mmHg and pressure lowering medication given) or posterior subcapsular cataract.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No